An Artificial Intelligence Approach to Proactively Inspire Drug Discovery with Recommendations.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
27 08 2020
Historique:
pubmed: 27 2 2020
medline: 15 12 2020
entrez: 27 2 2020
Statut: ppublish

Résumé

Artificial intelligence (AI) is becoming established in drug discovery. For example, many in the industry are applying machine learning approaches to target discovery or to optimize compound synthesis. While our organization is certainly applying these sorts of approaches, we propose an additional approach: using AI to augment human intelligence. We have been working on a series of recommendation systems that take advantage of our existing laboratory processes, both wet and computational, in order to provide inspiration to our chemists, suggest next steps in their work, and automate existing workflows. We will describe five such systems in various stages of deployment within the Novartis Institutes for BioMedical Research. While each of these systems addresses different stages of the discovery pipeline, all of them share three common features: a trigger that initiates the recommendation, an analysis that leverages our existing systems with AI, and the delivery of a recommendation. The goal of all of these systems is to inspire and accelerate the drug discovery process.

Identifiants

pubmed: 32101427
doi: 10.1021/acs.jmedchem.9b02130
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8824-8834

Auteurs

Steven L Rohall (SL)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Lydia Auch (L)

Novartis Institutes for BioMedical Research, Emeryville, California 94608, United States.

Jonathan Gable (J)

Novartis Institutes for BioMedical Research, Emeryville, California 94608, United States.

Jacob Gora (J)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Johanna Jansen (J)

Novartis Institutes for BioMedical Research, Emeryville, California 94608, United States.

Yipin Lu (Y)

Novartis Institutes for BioMedical Research, Emeryville, California 94608, United States.

Eric Martin (E)

Novartis Institutes for BioMedical Research, Emeryville, California 94608, United States.

Margaret Pancost-Heidebrecht (M)

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.

Bill Shirley (B)

Novartis Institutes for BioMedical Research, Emeryville, California 94608, United States.

Nikolaus Stiefl (N)

Novartis Institutes for BioMedical Research, CH-4056 Basel, Switzerland.

Mika Lindvall (M)

Novartis Institutes for BioMedical Research, Emeryville, California 94608, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH